Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 13/20 | 0.49 |
| ▸ | FEN1 | P39748 | 12/20 | 0.49 |
| ▸ | FPR1 | P21462 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749780 | 0.83 | PTPN1 (0.53) | FPR2ALOX5APFEN1FPR1 | |
| Cyclopentane SCHEMBL7093842 | 0.82 | FPR2 (0.52) | FPR2ALOX5APFEN1FPR1 | |
| SCHEMBL7364780 | 0.81 | ALOX5AP (0.51) | FPR2ALOX5APFEN1FPR1KMT2A | |
| SCHEMBL6752209 | 0.81 | ALOX5AP (0.48) | FPR2ALOX5APFEN1FPR1 | |
| SCHEMBL7061589 | 0.81 | ALDH1A1 (0.54) | FPR2ALOX5APFEN1FPR1KMT2A | |
| SCHEMBL7086229 | 0.77 | KMT2A (0.55) | KMT2AMEN1RAB9A | |
| SCHEMBL890827 | 0.77 | F10 (0.45) | FPR2ALOX5APFEN1FPR1KDM4E | |
| SCHEMBL1968159 | 0.77 | ALOX5AP (0.59) | ALOX5APFEN1 | |
| SCHEMBL6256286 | 0.77 | FPR2 (0.54) | FPR2ALOX5APFEN1FPR1KMT2A | |
| SCHEMBL7266386 | 0.77 | ALOX5AP (0.54) | ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | RCOR3, F2, NCOR2 | FPR2 138/4885ALOX5AP 1332/4885FEN1 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.